SMAD3 and breast cancer: Because the TGF-β/SMAD3 signaling can upregulate CXCR4 expression in breast cancer, promoting metastasis, and its ligand CXCL12 is enriched in the bone marrow microenvironment, we evaluated whether SOST silencing could change in the expression of these factors in SCP2 cells.